v3.25.2

Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2025	Jul. 31, 2024
Current assets:
Cash and cash equivalents	$ 36,693	$ 52,371
Cash in escrow		5,000
Accounts receivable, net	4,309	3,988
Inventories, net	5,714	6,832
Prepaid expenses and other current assets	1,562	1,840
Total current assets	48,278	70,031
Property, plant, and equipment, net	12,380	12,367
Right-of-use assets	2,472	2,836
Other assets	386	530
Total assets	63,516	85,764
Current liabilities:
Accounts payable – trade	1,395	1,376
Accrued liabilities	5,170	5,714
Current portion of operating lease liabilities	881	841
Other current liabilities	73	76
Current liabilities of discontinued operations, net	9,492	16,787
Total current liabilities	17,011	24,794
Operating lease liabilities, non-current	1,920	2,403
Long term debt	129	189
Non-current liabilities of discontinued operations, net	1,058	2,266
Total liabilities	20,118	29,652
Contingencies – see Note 13
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 52,402,804 at April 30, 2025 and 52,244,074 at July 31, 2024	523	521
Additional paid-in capital	343,333	348,134
Accumulated deficit	(302,129)	(294,428)
Accumulated other comprehensive income	1,671	1,885
Total stockholders’ equity	43,398	56,112
Total liabilities and stockholders’ equity	$ 63,516	$ 85,764

Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

ENZO BIOCHEM INC 10-Q